View Post

Circulating Tumor Cell Count Reliable in Determining Best Treatment Approach for Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

From: journalofclinicalpathways.com Circulating tumor cell count is a reliable biomarker for choosing between chemotherapy or endocrine therapy for patients with HER2-negative metastatic breast cancer, according to a recent study published in JAMA Oncology (2020 Nov 5. doi:10.1001/jamaoncol.2020.5660). “The choice between chemotherapy and endocrine therapy as first-line treatment for [HER2-negative] metastatic breast cancer is usually based on the presence of clinical …

View Post

FDA grants fast track designation to ARX788 for breast cancer subset

In In The News by Barbara Jacoby

Source: HemOnctoday From: healio.com The FDA granted fast track designation to ARX788 as monotherapy for certain patients with HER2-positive breast cancer. The designation applies to use of the agent for patients with advanced or metastatic disease who received at least one prior anti-HER2-based regimen in the metastatic setting. ARX788 (Ambrx) — an antibody-drug conjugate that targets the HER2 receptor — …

View Post

Enobosarm Shows Clinical Benefit in AR+, ER+ Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: onclive.com Enobosarm demonstrated clinical benefit at varying dose levels in patients with androgen receptor (AR)–positive, estrogen receptor (ER)–positive metastatic breast cancer, according to phase 2 findings of the G200802 study that were presented during the virtual 2020 San Antonio Breast Cancer Symposium.1,2 At the 9-mg and 18-mg doses of enobosarm, the 6-month clinical benefit rate (CBR) …

View Post

Phase 3 DETECT III Study Suggests CTC Count to be Possible Biomarker for HER2-Directed Therapy in MBC

In Clinical Trials by Barbara Jacoby

By: Dylann Cohn-Emery From: cancernetwork.com The study found that favorable outcomes after treatment with lapatinib (Tykerb) were demonstrated by early declines in circulating tumor cell counts (CTCs) in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs. Data from the phase 3 DETECT III study (NCT01619111) showed favorable outcomes after treatment with the HER2-directed …

View Post

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

In In The News by Barbara Jacoby

From: businesswire.combreast Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Latest findings from the breast cancer cohort in SUMMIT – a phase 2 ‘basket’ trial of neratinib + trastuzumab + …

View Post

Amcenestrant Demonstrates Intriguing Activity in Postmenopausal Advanced ER+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Mauro From: onclive.com Amcenestrant (SAR439859) elicited antitumor activity in heavily pretreated, postmenopausal women with advanced or metastatic estrogen receptor (ER)–positive breast cancer, according to phase 1/2 results of the AMEERA-1 trial (NCT03284957) that were presented during the 2020 San Antonio Breast Cancer Symposium.1 Results showed that the objective response rate (ORR) was 8.5% with amcenestrant with a clinical …

View Post

Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Cohort …

View Post

METAvivor and Ciitizen Announce Partnership and New Clinical Trial Search Tool

In In The News by Barbara Jacoby

From: prweb.com Metavivor Research and Support Inc., a national non-profit organization dedicated to funding research for stage IV metastatic breast cancer (MBC), announced a strategic partnership with consumer health tech company Ciitizen to bring a comprehensive new Clinical Trial Search Tool and Clinical Trial Matching Program to the stage 4 metastatic breast cancer community. Metavivor took up the mantle for …

View Post

Monitoring Metastatic Breast Cancer Treatment Response: 5 Things to Know

In In The News by Barbara Jacoby

By: Victoria Stern From: medscape.com The 5-year survival estimates for women with metastatic breast cancer (MBC) hover around 28%, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) data from 2010 to 2016. But closer scrutiny of the evolution of MBC care reveals a more promising outlook, according to Adam Brufsky, MD, PhD, associate chief of the …

View Post

Palbociclib Demonstrates Prolonged OS/PFS When Initiated in Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Tony Berberabe, MPH From: targetedonc.com Patients who received palbociclib and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients who received placebo and fulvestrant, according to an exploratory subgroup analysis of the phase 3 PALOMA-3 trial. Patients who received palbociclib (Ibrance) and fulvestrant before chemotherapy for metastatic breast cancer had greater clinical benefit versus patients …